These preclinical studies suggest that concurrent treatment with a Pim kinase inhibitor has the potential to sensitize AML cells with FLT3-ITD to the cytotoxic effects of topoisomerase 2 inhibitors, but not AraC. Here, FLT3 is linked to acute myeloid leukemia.